CAS: 2315-61-9; 4-Octylphenol Diethoxylate

该化合物是一种非离子表面活性剂,来源于4-et-oct-oct-oct-phenol 的代谢作用. 它具有极好的乳化,湿化和散射特性,适合工业和实验室应用. 化合物平衡的流体-脂性能确保与一系列配方相容,包括清洁剂,农用化学品和涂层. 它在不同的pH和温度条件下的稳定性增强了其在高要求环境中的效用. 两个乙氧基化合物组在水分和有机相中提供中等溶性,促进了其在特殊化学合成中的中间作用. 这种表面活性因其在多相系统中的一贯性能和可靠性而受到重视.

结构式图片

欧盟法规

[ECHA物质C&L通报

上下游产品

CAS号76790-62-0 ethyl 6-[p-(1',... | CAS号2315-67-5 4-叔辛基苯酚单氧化物 | CAS号29375-78-8 ethyl [p-(1,1,3... | CAS号59388-61-3 Natrium-[4-(1,1... | CAS号2315-62-0 Ethanol, 2-[2-[...

合成工艺路线路线简述

    📜辛基酚聚醚-3置于lithium Aluminium Tetrahydride,Sodium Hydride体系中,用 四氢呋喃 用作溶剂,化学反应 4.0H,反应生成2-[2-[4-(1,1,3,3-四甲基丁基)苯氧基]乙氧基]-乙醇
    参考文献:Isolation Of Bacterial Strains That Produce The Endocrine Disruptor,octylphenol Diethoxylates,In Paddy Fields
    标题:Isolation Of Bacterial Strains That Produce The Endocrine Disruptor,octylphenol Diethoxylates,In Paddy Fields
    摘要:从日本西部的36个不同水稻田收集了表层土壤样本.每个土壤样本都跟含有0.2% Oppeo的基础盐培养基一起孵育.十二个样本表现出oppeo降解活性,分别从中分离出十二种oppeo降解细菌.所分离的细菌在含有0.2% Oppeo作为唯一碳源的培养基上生长,在好氧条件下积累了op2Eo和op3Eo.在本实验中,通常与op2Eo一起在地表水中被识别的op1Eo和辛基酚并未被观测到.通过biolog和16S Rdna Rflp分析,所分离的细菌为革兰氏阴性,初步鉴定为假单胞菌(pseudomonas Putida,10个分离株)和伯克霍尔德菌(burkholderia Cepacia,一个分离株).
    Doi:10.1271/bbb.66.1792

    海关参考信息

    专利信息


    专利号:US-12421534-B2
    优先权日:2021-11-10
    标 题 :Engineered enzymes and method for the synthesis of diverse tyrosine analogs
    发明人:ALMHJELL PATRICK J; ARNOLD FRANCES H
    权利人:CALIFORNIA INST OF TECHN
    摘要:Provided herein is an engineered tryptophan synthase β-subunit (TrpB) that catalyzes the synthesis of tyrosine, tyrosine analogs, or salts thereof. Also provided herein are methods for preparing tyrosine, tyrosine analogs, or a salt thereof using the engineered TrpB described herein.

    专利号:US-11945838-B2
    优先权日:2018-12-20
    标 题:Method for synthesis of protein amphiphiles
    发明人:BRITTO Sandanaraj Selvaraj; REDDY Mullapudi Mohan
    权利人:INDIAN INSTITUTE OF SCIENCE EDUCATION AND RES
    摘要:The present invention discloses a novel cost effective method for synthesis of protein/peptide amphiphiles irrespective of functional and structural classification of proteins useful in designing a vaccine candidate from antigenic protein. The protein modification of the present invention is universal and hence any protein/peptide can be converted into amphiphilic proteins/peptides.

    专利号:US-2023313255-A1
    优先权日:2020-07-15
    标题:Massively Parallel Enzymatic Synthesis of Polynucleotides
    发明人:HORGAN ADRIAN; LACHAIZE HENRI; VERARDO DOMIANO; GODRON XAVIER
    权利人:DNA SCRIPT
    摘要:The invention is directed to methods and compositions for inkjet assisted synthesis of a plurality of polynucleotides at reaction sites on a substrate using template-free polymerases, such as, terminal deoxynucleotidyl transferases (TdTs). Compositions of the invention include formulations of synthesis reagents for inkjet delivery including, but not limited to, TdT coupling reaction buffers and 3′-O-protected dNTP monomers.

    专利号:US-2023183177-A1
    优先权日:2020-04-24
    标题:Enantioselective chemo-enzymatic synthesis of optically active amino amide compounds
    发明人:GRILL BIRGIT; WINKLER MARGIT; SCHWAB HELMUT; STROHMEIER GERNOT; DONSBACH KAI; WALDVOGEL SIEGFRIED R; ARNDT SEBASTIAN; WEIS DOMINIK
    权利人:PHARMAZELL GMBH
    摘要:The present invention relates to a novel biocatalytic process for the stereoselective preparation of alpha amino amide compounds catalyzed by NHase enzymes. A further aspect of the invention relates to novel NHase enzymes as well as further improved NHase enzyme mutants, nucleic acid molecules encoding these enzymes, recombinant microorganisms suitable for preparing such enzymes and mutants. Another aspect of the invention relates to a chemo-biocatalytic process for the preparation of lactam compounds comprising the new catalytic process for the preparation of alpha amino amide compounds catalyzed by NHase enzymes, as well as the chemical oxidation of the alpha amino amide by applying certain chemical oxidation catalysts suitable for converting the alpha amino amide under retention of its stereochemical configuration to the respective lactam. The novel chemo-biocatalytic process is particularly suited for the synthesis of valuable pharmaceutical compounds, like in particular (S)-Levetiracetam.

    专利号:US-2023078363-A1
    优先权日:2020-03-23
    标 题:Synthesis of amorphous and nanostructured lutetium borate hexahydrate and method for preparing stable colloidal dispersions
    发明人:BÜLBÜL BERNA
    权利人:VERTRATECH KIMYA SANAYI VE TICARET LTD SIRKETI
    摘要:The invention relates to a method for the synthesis of amorphous and nanostructured lutetium borate hexahydrate and a method for the preparation of stable colloidal dispersions with obtained lutetium borate hexahydrate having a hydrodynamic size below 150 nm, so as to be used in the field of material, medicine, textile and defense.

    专利号:US-12240835-B2
    优先权日:2018-09-18
    标题:Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity
    发明人:ROMERO F ANTHONY; KIRSCHBERG THORSTEN A; HALCOMB RANDALL; XU YINGZI
    权利人:TERNS PHARMACEUTICALS INC
    摘要:Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1007/s12031-010-9335-z
    摘要:Sanalkumar R, Vidyanand S, Lalitha Indulekha C, James J. Neuronal vs. Glial Fate of Embryonic Stem Cell-Derived Neural Progenitors (ES-NPs) is Determined by FGF2/EGF During Proliferation. Journal of Molecular Neuroscience. 2010 Feb 13;42(1):17–27. doi: 10.1007/s12031-010-9335-z.
    参考文献:10.1007/s00417-009-1282-4
    摘要:Hata Y, Miura M, Asato R, Kita T, Oba K, Kawahara S, Arita R, Kohno R, Nakao S, Ishibashi T. Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. Graefe's Archive for Clinical and Experimental Ophthalmology. 2010 Feb 13;248(5):667–73. doi: 10.1007/s00417-009-1282-4.
    参考文献:10.1007/s11596-010-0114-4
    摘要:Zhou S, Li F, Xiao J, Xiong W, Fang Z, Chen W, Niu P. Isolation and identification of cancer stem cells from human osteosarcom by serum-free three-dimensional culture combined with anticancer drugs. J Huazhong Univ Sci Technolog Med Sci. 2010 Feb;30(1):81–4. doi: 10.1007/s11596-010-0114-4.
    参考文献:10.1186/1471-2407-10-43
    摘要:Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, Lu Y, Cui Z, Qiu X. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer. 2010 Feb 16;10():43.
    参考文献:10.1007/s00702-010-0376-9
    摘要:Pérez-Cremades D, Hernández S, Blasco-Ibáñez JM, Crespo C, Nacher J, Varea E. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J Neural Transm (Vienna). 2010 Apr;117(4):445–55. doi: 10.1007/s00702-010-0376-9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知